J&J Prevails in Talc Lawsuit, Jury Finds No Negligence in Cancer Claims
JNJ sits 56% above its 52-week low of $149.04.
Summary
Johnson & Johnson secured a legal victory in a Los Angeles jury trial, successfully defending against claims that its talc products caused ovarian cancer in three women. This win is a positive development for J&J, which faces over 67,000 similar lawsuits. The verdict comes as trials have resumed following the recent voiding of J&J's Red River Talc bankruptcy plan, which had aimed to resolve these claims. This outcome provides a favorable data point for J&J in its ongoing, high-stakes talc litigation.
At the time of this announcement, JNJ was trading at $232.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $560.3B. The 52-week trading range was $149.04 to $251.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.